Genotype 4
Interleukin-28B with a predominance of G4 (90%) followed by genotype 1 [2, 3] . Host genetics controlling the immune-inflammatory pathways affects hepatic fibrosis [4] [5] [6] . Indeed, many studies reported that single nucleotide polymorphism (SNP) in proximity to interlukin-28B (IL28B) interferon-ë (IFN-ë) region (rs12979860) is a predictor of sustained virological response (SVR) to IFN-based therapy [7] [8] [9] [10] [11] .Several reports have showed that the rs12979860 'CC'genotype is associated with greater inflammation grade [12] [13] [14] . The relation of rs12979860 'CC' genotype to hepatic fibrosis progression, however, is controversial [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The present study involved only chronic hepatitis C (CHC)-G4 patients treated in a single center and aimed to clarify the impact ofrs12979860 gene polymorphisms on hepatic fibrosis; to explore the interactions of rs12979860 genotype with host and viral factors; and to explore the impact of rs12979860 genotype on SVR to antiviral therapy in the same group of patients.
Hepatic fibrosis Genetics

Abstract:
Recently, several genome wide association studies (GWAS) have revealed that several single nucleotide polymorphisms (SNPs) in proximity to the interleukin (IL)-28B genes can predict spontaneous clearance of hepatitis C virus (HCV) infection as well as sustained virological response (SVR) to Pegylated interferon-2a/b plus ribavirin therapy. In HCV-genotype 1 patients, the allele rs12979860 is associated with greater hepatic necro-inflammation and worse clinical outcome, but lower fibrosis progression. Data on patients infected with HCV genotype 4 (G4) is limited. The present study assesses the impact of rs12979860 IL28 SNP on hepatic fibrosis and SVR in patients with chronic HCV G4 infection. A total of 163 patients with chronic HCV G4 infection (123 males and 40 females) who had pre-treatment
Patients and Methods
Patients
A total of 163 patients with chronic
HCV-infection attending the Egyptian
Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt were included in this study.
Approvals
The study protocol conformed to the Test was done by Chi-Square and the Fisher's Exact tests.
Severe hepatic fibrosis
Compared to patients with nonsevere fibrosis stage (F0-2), patients with severe fibrosis (F3-4) were older (P = 0.002), had higher BMI (P = 0.016), higher serum ALT (P = 0.000), higher serum AST (P = 0.000), lower serum albumin (P = 0.016), higher serum alkaline phosphatase (P = 0.000), and more severe hepatic inflammation (P = 0.000). The similar percentages(P = 0.552) of SVR and no-SVR in patients with severe fibrosis (F3-4) and those without (F0-2) are shown in Figure 2 . Confirming the importance of inflammation grade in predicting severe hepatic fibrosis (F3-4), severe inflammation (A3-4) was detected in 9.1% and 80% of patients with F0-2 and those with F3-4, respectively (P = 0.000; Figure 3 ).Using multivariate logistic regression analysis, the independent predictors of severe fibrosis (F3-4) were age, serum AST, serum albumin, and inflammation grade, table (4).
Sustained virological response (SVR)
Compared to non-responders, patients who achieved SVR were similar regarding demographic, biochemical, virological, and pathological parameters. A total of 25/85(29.4%) of patients who achieved SVR and only 2/78 (2.6%) of those who did not had the "CC" allele of the rs129798660 gene (P = 0.001). Using multivariate logistic regression analysis, the independent predictors of SVR was only the CC allele of the rs12979860 gene (P = 0.000; OR: 0.07; CI: 0.02-0.29, table (3). progression on paired biopsies [13] . These findings are difficult to reconcile because hepatic fibrosis is a consequence of inflammation [1, 25] . Also, inflammation grade on initial liver biopsy is the best predictor of fibrosis progression [26, 27] . A recent meta-analysis of 28 studies that included 10,024 patients failed to resolve this controversy [28] , probably reflecting the inter-study variability in the outcomes.
In agreement with our results, a large study message is that once a patient's genotype is rs12979860 "CC", treatment needs to be given as soon as possible to benefit from good response to therapy, otherwise more fibrosis progression will be the consequence.
Conclusion
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